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Abstract
Background: Fluoroquinolones are potent antimicrobial agents used for the treatment of a wide variety of 
community- and nosocomial- infections. However, resistance to fluoroquinolones in Enterobacteriaceae is increasingly 
reported. Studies assessing the ability of fluoroquinolones to select for resistance have often used antimicrobial 
concentrations quite different from those actually acquired at the site of infection. The present study compared the 
ability to select for resistance of levofloxacin, ciprofloxacin and prulifloxacin at concentrations observed in vivo in 
twenty strains of Escherichia coli and Klebsiella spp. isolated from patients with respiratory and urinary infections. The 
frequencies of spontaneous single-step mutations at plasma peak and trough antibiotic concentrations were 
calculated. Multi-step selection of resistance was evaluated by performing 10 serial cultures on agar plates containing a 
linear gradient from trough to peak antimicrobial concentrations, followed by 10 subcultures on antibiotic-free agar. E. 
coli resistant strains selected after multi-step selection were characterized for DNA mutations by sequencing gyrA, gyrB, 
parC and parE genes.
Results: Frequencies of mutations for levofloxacin and ciprofloxacin were less than 10-11 at peak concentration, while 
for prulifloxacin they ranged from <10-11 to 10-5. The lowest number of resistant mutants after multistep selection was 
selected by levofloxacin followed by ciprofloxacin and prulifloxacin. Both ciprofloxacin- and prulifloxacin-resistant 
mutants presented mutations in gyrA and parC, while levofloxacin resistance was found associated only to mutations in 
gyrA.
Conclusions: Among the tested fluoroquinolones, levofloxacin was the most capable of limiting the occurrence of 
resistance.
Background
Escherichia coli is worldwide the most frequent pathogen
isolated from uncomplicated urinary tract infections
(UTI) (70 - 95%) and, in bacteremia of nosocomial or
community origin, it represents about the 15.5% and
42.1% of aetiologies, respectively [1]. Also Klebsiella spp.,
especially Klebsiella pneumoniae, are involved in uncom-
plicated UTI for 5% and represent 4.1% of bacteremias,
the mortality of nosocomial infections being more than
twice that of community-acquired infection [1,2].
Fluoroquinolones (FQ) are potent antimicrobial agents
used for the treatment of a wide variety of community-
and nosocomial- infections. However, increasing resis-
tance to FQ in E. coli isolated from community acquired
UTI has been recently reported, with up to 29% of
women harbouring FQ resistant E. coli, although FQ
resistance rates varied significantly according to sex, age,
type of urinary infection and geographic region [3-6].
Moreover, infections due to extended-spectrum beta-lac-
tamases (ESBL) - producing Enterobacteriaceae are an
emerging problem in the community since an high pro-
portion of these microorganisms have been isolated from
urine samples of women with uncomplicated UTI [7].
Ciprofloxacin use and ESBL production have been
shown to be significantly correlated in a study on K.
pneumoniae [8]. ESBL-producing strains have been
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Page 2 of 7shown to be significantly more frequent among ciproflox-
acin-resistant E. coli than among ciprofloxacin-suscepti-
ble E. coli strains [9]. Moreover, prior use of FQs, an
indwelling urinary catheter, and an invasive procedure
within 72 hr prior to bacteremia have been identified as
independent risk factors for ciprofloxacin resistance in
bloodstream infections due to ESBL E. coli and Klebsiella
spp. [2,10-12].
Several studies have assessed the ability of FQs to select
for resistance by subculturing bacteria at concentrations
close to MICs. However, the antimicrobial concentrations
used in these studies were quite different from those
actually acquired at the site of infection [13-16]. For these
reasons, we have recently modified the methodologies
used to assess in vitro the selection for resistance by test-
ing antimicrobial concentrations reported to occur in
vivo [17]. The aim of the present study was to compare
the ability of levofloxacin, ciprofloxacin and prulifloxacin
to in vitro select for resistance in E. coli and Klebsiella
spp. clinical isolates at peak (Cmax) and trough (Cmin)
plasma concentrations.
Results
Susceptibility to fluoroquinolones
Basal MICs of E. coli strains ranged from 0.016 mg/L to 1
mg/L, from 0.004 mg/L to 0.5 mg/L and from 0.016 mg/L
to 0.125 mg/L for levofloxacin, ciprofloxacin and pruli-
floxacin, respectively. MICs of Klebsiella spp. ranged
between 0.03 mg/L and 1 mg/L, 0.016 mg/L and 0.5 mg/
L, and 0.03 and 0.25 mg/L for levofloxacin, ciprofloxacin
and prulifloxacin, respectively.
Frequency of mutation
Levofloxacin, 500 and 750 mg, and ciprofloxacin 500 mg
limited bacterial growth with median frequencies of
mutations below 10-11 at plasma Cmax. Median frequen-
cies of mutations for prulifloxacin were generally higher
than comparators ranging from 10-7 to 10-8 and from 10-8
to 10-9 at plasma Cmax in E. coli and Klebsiella spp.,
respectively (Table 1). Table 2 shows MIC values of the
strains that were able to grow in the presence of the above
mentioned concentrations of all tested antimicrobials.
While no strain was able to grow at Cmax for levofloxacin
and ciprofloxacin, 3 and 5 strains grew at prulifloxacin
Cmax. These strains showed increments in MICs from 32
to 128 times for E. coli and from 32 to 128 times for Kleb-
siella spp. with respect to the basal values. Since in some
instances, Cmin for all the study drugs, except for levo-
floxacin at 750 mg dosage, were below MIC values, some
strains were able to diffusely grow on the agar plate. For
these strains, in order to detect any change in bacterial
susceptibility, MICs were evaluated for randomly sam-
pled colonies (Table 2).
Multi-step selection of resistant bacteria
Table 3 shows the total number of strains grown after
multi-step selection and MIC values after 1, 5 and 10 pas-
sages on antibiotic-gradient plates and after the subse-
quent 10 passages on antibiotic-free medium. After
multi-step selection, a general increment in MICs was
observed for all microrganisms with all tested antibiotics;
no selection of resistance was observed with levofloxacin
at 750 mg in E. coli and no selection of resistance was
observed with levofloxacin (both doses) in Klebsiella spp.
After 10 passages on antibiotic gradient plates and 10
subcultures in antibiotic-free medium, the highest num-
ber of strains with MIC higher than the resistance break-
point was found for ciprofloxacin and prulifloxacin both
in E. coli (5 and 7 strains, respectively) and Klebsiella spp.
(6 and 8 strains, respectively). Only 4 strains with MIC
higher than resistance breakpoint were found with levo-
floxacin at 500 mg in E. coli and Klebsiella spp., whereas
no resistant strains selected with the 750 mg either in E.
coli or in Klebsiella spp. (Figure 1).
Characterization of acquired resistance
Strains of E. coli that were selected by the multi-step
assay and were able to maintain their resistance after 10
passages in antibiotic-free medium, were evaluated for
acquired resistance.
Among 16 resistant mutants, alterations in both gyrA
and parC were found in 12 mutants for ciprofloxacin (n =
5) and prulifloxacin (n = 7), while only alterations in gyrA
were found for levofloxacin. As reported in table 4, the 4
strains resistant to levofloxacin showed changes in
Ser83Leu and Asp87Asn; while in ciprofloxacin- and
prulifloxacin-resistant mutants, the mutations identified
were Ser83Leu in GyrA and Ser80Ile in ParC. The same
mutations were not found in the respective parent
strains.
Discussion
Wild-type E. coli and K. pneumoniae clinical isolates are
susceptible to quinolones, but resistance to these agents
in Gram-negative bacteria has increased in recent years,
probably caused by excessive and inappropriate use of
these drugs [18]. Particularly, due to under-dosing and
mono-therapy against moderately susceptible pathogens,
FQ resistance has developed among common pathogens,
like E. coli and Klebsiella spp., mainly conferred by ESBLs
and AmpC enzymes [19]. ESBL production has been
reported to be two times more common in infected
patients who received ciprofloxacin than in those who
did not (15% vs 7.4%) [8].
In a study performed over 5 years in Croatia on changes
in susceptibility of E. coli from UTI, Moeal et al have
shown a statistically significant change in antimicrobial
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This has been hypothesized to be related to the inappro-
priate use of quinolones for humans as well as in veteri-
nary medicine [21]. Prolonged use (> 20 days) of low dose
(250 mg twice a day) of the more potent fluoroquinolones
such as ciprofloxacin or levofloxacin, has been shown to
be the most significant risk factor for acquisition of resis-
tance [22,23]. Strategies to counteract bacterial resis-
tances include use of the appropriate dosages of these
molecules for the correct indication and/or use of syner-
gistic combinations, particularly in the more complicated
infections.
Results of this study indicate that levofloxacin presents
the lowest frequencies of mutations at plasma Cmax
(<10-11) and a lower propensity than prulifloxacin or cip-
rofloxacin to select in vitro for resistance. In regard to
genetic characterization of resistance, only alterations in
gyrA were found for levofloxacin, however, alterations in
gyrA and parC were found for ciprofloxacin and pruli-
floxacin. Point mutations within DNA gyrase are known
to cause a reduction in the affinity of the enzyme for FQs,
decreasing the susceptibility of bacteria to these mole-
cules. Topoisomerase IV is the second target for FQ in
the absence of susceptible gyrase. Therefore, multiple
mutations in gyrA and/or parC are required for high level
Table 1: Frequency of mutation at plasma antimicrobial concentrations in E. coli and Klebsiella spp.
Drug Frequency of mutation
E. coli (n = 20) Klebsiella spp. (n = 20)
Cmax Cmin * Cmax Cmin*
LVX 500 mg
Range <10-11 < 10-11 - 1.0 × 10-7 <10-11 <10-11 - 7.4 × 10-5
median <10-11 2.0 × 10-11 <10-11 7.9 × 10-8
LVX 750 mg
Range <10-11 <10-11 - 2.7 × 10-5 <10-11 <10-11 - 7.7 × 10-6
median <10-11 <10-11 <10-11 2.2 × 10-8
CIP 500 mg
Range <10-11 <10-11 - 6.3 × 10-6 <10-11 3.2 × 10-8 - 8.5 × 10-5
median <10-11 <10-11 <10-11 1.5 × 10-7
PRU 600 mg
Range <10-11 - 2.4 × 10-6 < 10-11 - 4.1 × 10-6 <10-11 - 1.7 × 10-5 6.3 × 10-9- 2.2 × 10-5
median 4.3 × 10-8 2.4 × 10-7 6.7 × 10-9 7.1 × 10-7
LVX: Levofloxacin; CIP: Ciprofloxacin; PRU: Prulifloxacin; Cmax: peak plasma concentration; Cmin: trough plasma concentration
* Frequency of mutations was calculated only for strains with MIC < Cmin.
Table 2: Fluoroquinolone activity on strains grown after single step selection in E. coli and Klebsiella spp. at plasma 
concentrations
Drug MIC range (mg/L)/number of strains grown
E. coli (n = 20) Klebsiella spp. (n = 20)
Cmax Cmin* Cmax Cmin*
LVX 500 mg -/0 1/1 -/0 0.5 - 4/16
LVX 750 mg -/0 1 - 4/2 -/0 1 - 8/14
CIP 500 mg -/0 0.25 - 0.5/4 -/0 0.125 - 4/20
PRU 600 mg 2 - 4/3 0.25 - 2/5 4 - 8/5 0.06 - 1/20
LVX: Levofloxacin; CIP: Ciprofloxacin; PRU: Prulifloxacin; Cmax: peak plasma concentration; Cmin: trough plasma concentration
* MICs were evaluated for all the tested strains
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floxacin and prulifloxacin resistant mutants presented
mutations in gyrA and parC, while levofloxacin resistance
was found associated only with mutations in gyrA. These
results seem to indicate that levofloxacin resistance at a
concentration observed during treatment might develop
more slowly and might be lower than resistance to the
other FQs tested in the present study.
However, this study did not evaluated other mecha-
nisms other than the target enzyme that might be
involved in the observed resistant strains, including
decreased intracellular drug accumulation as a result of
alterations in the outer membrane proteins of the wall
cell, or active efflux of the drug mediated by a number of
efflux pumps.
As far as FQ resistance in Klebsiella spp. is concerned,
plasmid-mediated quinolone resistance mechanisms
associated with the qnr gene and the aac(6')-Ib-cr gene in
ESBL producing strains have been described [25,26]. The
first encodes target protection proteins of the pent pep-
tide repeat family and seems to be associated with low
level quinolone resistance, while the aac(6')-Ib-cr gene
encodes a variant of the common aminoglycoside acetyl-
transferase which is able to reduce the activity of some
FQ, thus enhancing the selection of chromosomal muta-
tions [25]. Although in the present study the presence of
plasmid-mediated resistance was not investigated, it can
not be excluded that these genes might be involved in
selection of resistance observed after serial exposure to
fluoroquinolones.
In a previous study, we have shown that combinations
of a fluoroquinolone with a beta-lactam may both pro-
vide improved antimicrobial activity and limit the occur-
rence of resistance in ESBL-producing E. coli clinical
isolates [27]. Therefore, the use of combination therapy
could be an attractive strategy to limit occurrence of
resistance.
Conclusions
In conclusion, among the tested fluoroquinolones, levo-
floxacin was the most able to limit occurrence of resis-
tance in vitro. However, in order to limit the occurrence
of resistance, appropriate dosages of fluoroquinolones
should be respected in the therapy of infections caused by
Enterobacteriaceae, as well as use of synergistic combina-
tions in the most complicated infections.
Table 3: MIC values after multi-step selection of resistance in E. coli and Klesiella spp. at plasma concentration of 
fluoroquinolones
Drug MIC (mg/L): median (range)
Nr of strains Pre-sel I STEP V STEP X STEP X STEP
free
E. coli (n = 20)
LVX
500 mg
7 0.5
(0.5 - 1)
2
(0.5-4)
4
(1 - 8)
8
(2 - 8)
4
(1 - 8)
LVX
750 mg
0 0.016 - 1 n.d. n.d. n.d. n.d.
CIP
500 mg
8 0.25
(0.125 - 0.5)
0.5
(0.125 - 1)
2
(2 - 4)
8
(4 - 16)
4
(1 - 8)
PRU
600 mg
12 0.064
(0.016 - 0.125)
1
(0.5 - 4)
2
(2 - 4)
4
(2 - 8)
4
(2 - 8)
Klebsiella spp. (n = 20)
LVX
500 mg
0 0.03 - 1 n.d n.d n.d n.d
LVX
750 mg
0 0.03 - 1 n.d n.d n.d n.d
CIP
500 mg
11 0.06
(0.03 - 0.5)
0.5
(0.5 - 1)
2
(1 - 8)
8
(4 - 16)
4
(1 - 4)
PRU
600 mg
16 0.06
(0.03 - 0.25)
0.5
(0.06 - 1)
2
(0.25 - 16)
4
(0.5 - 32)
4
(0.25 - 16)
LVX: Levofloxacin; CIP: Ciprofloxacin; PRU: Prulifloxacin; Pre-sel: MICs before starting multi-step selection of resistance; I Step: MICs after the 
first passage on antibiotic gradient agar plates; V Step: MICs after the fifth passage on antibiotic gradient agar plates; X Step: MICs after the 
last passage on antibiotic gradient agar plates; X step free: MICs after ten subcultures on antibiotic free agar plates.
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Strains
Twenty clinical isolates of E. coli and Klebsiella spp., col-
lected from patients presenting with community infec-
tions in 2005 at L. Sacco Hospital, Milan, were included
into the study. Susceptibility to the drugs under evalua-
tion was considered as a pre-requisite for the study. One
isolate per patient was used in order to avoid inclusion of
the same strain. All isolates were stored at -80°C in brain-
heart infusion broth containing 10% (w/v) glycerol until
use.
Antibiotics
Levofloxacin (sanofi-aventis, S.p.A. Milan, Italy); cipro-
floxacin (Bayer Italia, S.p.A., Milan, Italy), and prulifloxa-
cin (Aziende Chimiche Riunite Angelini Francesco
ACRAF S.p.A, S. Palomba-Pomezia, Italy) were used to
prepare stock solutions at concentrations of 5120 mg/L.
Plasma maximum and minimum concentrations (Cmax,
Cmin) of each antimicrobial studied were chosen from
those obtained at steady state in previously published
studies after oral administration [28-31]. Thus, the Cmax
were as following: levofloxacin 500 mg (5.29 mg/L); levo-
floxacin 750 mg (11.98 mg/L); ciprofloxacin 500 mg (2.11
mg/L); prulifloxacin 600 mg (2 mg/L) [28-31]. The tested
plasma Cmin were respectively: 0.60 mg/L for levofloxa-
cin 500 mg; 1.69 mg/L for levofloxacin 750 mg; 0.08 mg/L
for ciprofloxacin 500 mg; 0.10 mg/L for prulifloxacin 600
mg [28-31].
Determination of MIC
Antibiotic susceptibilities to the study drugs were deter-
mined by the microdilution broth assay in accordance
with CLSI approved standards [32]. Since no CLSI break-
points for prulifloxacin against E. coli and Klebsiella spp.
were available, reduced susceptibility to this agent was
defined as a MIC ≥ 4 mg/L [32]. Resistance to levofloxa-
Figure 1 Multi-step selection of resistance in E. coli (A) and Klebsiella spp. (B) at plasma concentration of fluoroquinolones. 1, 5, 10 step: num-
ber of passages on antibiotic gradient agar plates. 10 step free: passages on antibiotic free agar plates. Black bars: prulifloxacin; White bars: ciproflox-
acin; Dotted bars: levofloxacin.
0 5 10
1 STEP
5 STEP
10 STEP
10 STEP
FREE
Nr of strains with MIC> breakpoint
0 5 10 15
1 STEP
5 STEP
10 STEP
10 STEP
FREE
Nr of strains with MIC> breakpoint
A B
Table 4: Amino acid changes encoded by mutations in gyrA, gyrB, parC, and parE in E. coli
Replacement in QRDR
Drug GyrA GyrB ParC ParE
LVX
(n = 4)
Ser83Leu (4)
Asp87Asn (4)
- - -
CIP
(n = 5)
Ser83Leu (5) - Ser80Ile (5) -
PRU
(n = 7)
Ser83Leu (7) - Ser80Ile (7) -
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4 mg/L, respectively [33].
Frequency of mutation
Colonies from an overnight culture in Mueller Hinton
agar were resuspended in brain heart infusion (BHI)
broth at a load of about 1010 CFU/mL. An aliquot of 100
μL from the bacterial suspension was spread onto Muel-
ler Hinton agar plates containing antibiotics at plasma
Cmax and Cmin, as reported above. After incubation for
72 h, the frequency of mutation was calculated from the
ratio between colonies grown on antibiotic-containing
plates and the initial inoculum, determined by plating 100
μL of bacterial suspension, after proper dilution, onto
Mueller Hinton agar plates. Five colonies from each anti-
biotic containing plate were randomly selected and their
MIC for the corresponding antibiotic was determined as
described above. When MIC was higher than the tested
concentration, as occurred for Cmin for some strains, so
that colony counts was not possible because of extensive
growth on plate surface, frequency of mutation was not
calculated, but the MIC was equally determined.
Multi-step selection of resistant bacteria
The ability to select for antibiotic resistance was evalu-
ated by performing serial subcultures on Mueller Hinton
agar plates, containing a gradient ranging from Cmax to
Cmin. Gradients were prepared in Petri dishes, which
were poured with two layers of agar, as described else-
where [34]. The bottom layer consisted of Mueller Hinton
agar containing the antibiotic at Cmin, which was
allowed to harden with the plate slanted sufficiently to
cover the entire bottom. The top layer, added to the dish
in the normal position, contained antibiotics at Cmax.
An inoculum of 1010 CFU/mL of each strain was
homogenously spread onto each plate and incubated for
48 hrs at 37°C. After incubation, colonies grown at the
highest drug concentration were sampled, checked for
purity, and re-plated on a new antibiotic-containing agar
plates. A total of 10 consecutive passages on antibiotic
containing plates were followed by 10 passages on antibi-
otic-free plates in order to evaluate stability of acquired
resistance. MIC values were determined after 1, 5 and 10
passages on antibiotic containing plates and after 5 and
10 passages in antibiotic free medium in order to evaluate
stability of acquired resistance. Acquisition of resistance
was defined as a MIC value higher than resistance break-
point.
Characterization of acquired resistance
To determine whether E. coli mutants that had acquired
stable resistance to quinolones had alterations in topoi-
somerase IV or DNA gyrase, parC, parE, gyrA, and gyrB
were amplified by PCR and sequenced as described pre-
viously [35].
Amplification products were purified with the
QIAquick PCR purification kit (Qiagen Inc., Milan Italy)
using the manufacturer's instructions. Sequencing was
performed on an ABI PRISM 310 genetic analyzer
(Applied Biosystems, Monza, Italy).
Only mutations known to be associated with resistance
to fluoroquinolones were considered (Ser83, Asp87 and
Ala93 in GyrA, Ser80 and Glu84 in ParC) [36].
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